115 Participants Needed

Ustekinumab for Crohn's Disease and Ulcerative Colitis

WA
Overseen ByWaqqas Afif, MD
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Must be taking: Ustekinumab
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST).

The main question it aims to answer is:

Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission.

Participants will:

Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Are You a Good Fit for This Trial?

This trial is for individuals with Crohn's Disease or Ulcerative Colitis who are in clinical and endoscopic remission, not using corticosteroids. Women must either be unable to have children or use reliable birth control. Participants must also give informed consent and be in biochemical remission.

Inclusion Criteria

My condition is currently in remission.
My latest endoscopy showed no signs of my disease.
I am not taking corticosteroids.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo de-escalation of ustekinumab therapy, changing dosing from every 4 weeks to every 8 weeks or from every 8 weeks to every 12 weeks

12 months
4-6 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Ustekinumab

Trial Overview

The study tests if patients can maintain remission when the dose of Ustekinumab (UST) is reduced from every 4 weeks to every 8 weeks, or from every 8 weeks to every 12 weeks. It monitors UST blood levels, inflammation markers, and intestinal health during less frequent dosing.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Ustekinumab Q8wExperimental Treatment1 Intervention
Group II: Ustekinumab Q4wExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

McGill University Health Centre/Research Institute of the McGill University Health Centre

Lead Sponsor

Trials
476
Recruited
170,000+

Janssen Inc.

Industry Sponsor

Trials
24
Recruited
8,100+